{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:29:31Z","timestamp":1782473371556,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RD06\/0010\/0013"],"award-info":[{"award-number":["RD06\/0010\/0013"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.neuropharm.2013.07.016","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T21:23:31Z","timestamp":1377033811000},"page":"156-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"PA","title":["Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA"],"prefix":"10.1016","volume":"76","author":[{"given":"Antonio","family":"Dominguez-Meijide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Villar-Cheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garrido-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Sierrra-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Labandeira-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.07.016_bib1","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1523\/JNEUROSCI.0918-12.2012","article-title":"Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors","volume":"32","author":"Anzalone","year":"2012","journal-title":"J.\u00a0Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2013.07.016_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001971","article-title":"Carbidopa\/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design","volume":"2","author":"Brodell","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1476-5381.1996.tb15418.x","article-title":"Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in\u00a0vitro and in\u00a0vivo","volume":"118","author":"Brown","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2013.07.016_bib4","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in l-dopa-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00424-009-0725-4","article-title":"Angiotensin receptors as determinants of life span","volume":"459","author":"Cassis","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0022-3565(25)33361-6","article-title":"Operational characteristics of the inhibitory feedback mechanism for regulation of dopamine release via presynaptic receptors","volume":"223","author":"Cubeddu","year":"1982","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2008.12.002","article-title":"Getting specialized: presynaptic and postsynaptic dopamine D2 receptors","volume":"9","author":"De Mei","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00165730","article-title":"DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum","volume":"345","author":"Dwoskin","year":"1992","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF03160175","article-title":"Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain","volume":"19","author":"Fornaretto","year":"1993","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MNH.0b013e32831a9e0b","article-title":"Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance","volume":"18","author":"Gildea","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00004872-200205000-00026","article-title":"Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats","volume":"20","author":"Gohlke","year":"2002","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-2-1","article-title":"Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra","volume":"2","author":"Grammatopoulos","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)32511-5","article-title":"The site of dopamine formation in rat striatum after l-dopa administration","volume":"217","author":"Hefti","year":"1981","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-328X(96)00157-X","article-title":"Effects of l-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys","volume":"42","author":"Herrero","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","article-title":"Correlation of apomorphine and amphetamine \u2013 induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats","volume":"626","author":"Hudson","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/01.HYP.32.6.1054","article-title":"Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules","volume":"32","author":"Hussain","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neulet.2008.08.021","article-title":"Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats","volume":"444","author":"Jenkins","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","article-title":"The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease","volume":"109","author":"Joglar","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(07)70077-7","article-title":"Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?","volume":"6","author":"Kehoe","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib21","doi-asserted-by":"crossref","first-page":"F1110","DOI":"10.1152\/ajprenal.90336.2008","article-title":"Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells","volume":"295","author":"Khan","year":"2008","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib22","first-page":"226","article-title":"Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease","volume":"1","author":"Labandeira-Garcia","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0306-4522(00)00588-1","article-title":"Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum","volume":"103","author":"Lopez","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(03)02291-1","article-title":"Localization and functional significance of striatal neurons immunoreactive to aromatic l-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models","volume":"969","author":"Lopez-Real","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00004647-200405000-00008","article-title":"Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat","volume":"24","author":"Lou","year":"2004","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2008.05.003","article-title":"Role of the renin-angiotensin system in vascular inflammation","volume":"29","author":"Marchesi","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib27","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling, physiological and pathological effects in the cardiovascular system","volume":"29","author":"Mehta","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-8993(93)90902-Y","article-title":"Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats1993","volume":"613","author":"Mendelsohn","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1460-9568.2011.07840.x","article-title":"The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death","volume":"34","author":"Mertens","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.arr.2008.12.002","article-title":"Signaling mechanisms of angiotensin II in regulating vascular senescence","volume":"8","author":"Min","year":"2009","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/hr.2009.110","article-title":"Effects of angiotensin II receptor blockers on dementia","volume":"32","author":"Mogi","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib32","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia","volume":"131","author":"Mu\u00f1oz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib34","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00109-008-0331-5","article-title":"Brain renin angiotensin in disease","volume":"86","author":"Phillips","year":"2008","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib36","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.1073\/pnas.0903958106","article-title":"Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity","volume":"106","author":"Platten","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0025-7125(03)00124-X","article-title":"Tissue renin angiotensin systems","volume":"88","author":"Re","year":"2004","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.neurobiolaging.2006.02.018","article-title":"Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons","volume":"28","author":"Rey","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","article-title":"Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS","volume":"31","author":"Rodriguez-Pallares","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s11357-012-9470-2","article-title":"Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage","author":"Rodriguez-Perez","year":"2013","journal-title":"Age (Dordr.)"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/brain\/awr320","article-title":"Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system","volume":"135","author":"Rodriguez-Perez","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1385-299X(97)00034-2","article-title":"An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism","volume":"2","author":"Rozas","year":"1997","journal-title":"Brain Res. Brain Res. Protoc."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(96)01162-6","article-title":"Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test","volume":"749","author":"Rozas","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0270(98)00078-8","article-title":"The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism","volume":"83","author":"Rozas","year":"1998","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib45","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/mds.21945","article-title":"A\u00a0case of parkinsonism worsened by losartan: a probable new adverse effect","volume":"23","author":"Sarma","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib46","first-page":"229","article-title":"Use-dependent structural events in recovery of function","volume":"73","author":"Schallert","year":"1997","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib47","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1073\/pnas.0903602106","article-title":"Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system","volume":"106","author":"Stegbauer","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib48","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1523\/JNEUROSCI.16-23-07776.1996","article-title":"Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons","volume":"16","author":"Todd","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib49","first-page":"H11","article-title":"Pharmacological aspects of candesartan, an effective AT1-receptor blocker","author":"Unger","year":"2004","journal-title":"Eur. Heart J. (Supplement H)"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib50","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/npp.2012.152","article-title":"Candesartan, an angiotensin AT1-receptor blocker and PPAR-\u03b3 agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice","volume":"37","author":"Villapol","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib51","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1460-9568.2010.07448.x","article-title":"Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease","volume":"32","author":"Villar-Cheda","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.08.006","article-title":"Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration","volume":"33","author":"Villar-Cheda","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.07.016_bib53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases","volume":"465","author":"Wright","year":"2013","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.RES.0000240500.96746.ec","article-title":"Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells","volume":"99","author":"Zeng","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2013.07.016_bib55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.0000085334.34963.4E","article-title":"Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats","volume":"42","author":"Zeng","year":"2003","journal-title":"Hypertension"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081300333X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081300333X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:54:36Z","timestamp":1762214076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081300333X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":55,"alternative-id":["S002839081300333X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}